Literature DB >> 1847418

Suppression of human neutrophil functions by tetracyclines.

W L Gabler1, H R Creamer.   

Abstract

Tetracycline inhibition of neutrophil-associated collagenolysis has been the focus of a number of investigations. Evidence has suggested that this inhibition results from the ability of this family of antimicrobial drugs to bind divalent cations such as Ca2+ and Zn2+, two cations that are required for full expression of activity of metalloproteinases such as collagenase and gelatinase. Data presented in this study demonstrate that tetracyclines can also inhibit neutrophil-mediated RBC lysis, superoxide anion synthesis, degranulation and migration. To some extent, tetracycline inhibition of neutrophil functions is mimicked by the Ca2+ binding agents, EDTA and TMB-8. However, Ca2+ enrichment restored full function to EDTA- and TMB-8-treated cells but not to tetracycline-treated neutrophils. This suggests that Ca2+ binding plays a role but is not the critical effect leading to tetracycline suppression of neutrophil functions. It has been suggested that tetracyclines can suppress leukocyte-associated tissue damage. Host tissues are protected from neutrophil-mediated damage by two mechanisms: 1. Neutrophil granule-associated enzymes are secreted in an inactive state; and, 2. tissues are protected from these enzymes by a potent inhibitor shield. Neutrophils can bypass these protective elements by activating enzymes and by destroying the shield through the synthesis of oxygen radicals. Therefore, tetracyclines may suppress neutrophil-mediated tissue damage by inhibiting their migration and degranulation and, potentially more importantly, by suppressing synthesis of oxygen radicals.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847418     DOI: 10.1111/j.1600-0765.1991.tb01626.x

Source DB:  PubMed          Journal:  J Periodontal Res        ISSN: 0022-3484            Impact factor:   4.419


  37 in total

Review 1.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 2.  Tetracyclines and pain.

Authors:  Leandro F S Bastos; Antônio C P de Oliveira; Linda R Watkins; Márcio F D Moraes; Márcio M Coelho
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-01-27       Impact factor: 3.000

3.  Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis.

Authors:  Damian N Meli; Roney S Coimbra; Dominik G Erhart; Gerard Loquet; Caroline L Bellac; Martin G Täuber; Ulf Neumann; Stephen L Leib
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

4.  Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia.

Authors:  J Yrjänheikki; R Keinänen; M Pellikka; T Hökfelt; J Koistinaho
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

5.  Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia.

Authors:  T Tikka; B L Fiebich; G Goldsteins; R Keinanen; J Koistinaho
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

Review 6.  The neuroimmunology of degeneration and regeneration in the peripheral nervous system.

Authors:  A DeFrancesco-Lisowitz; J A Lindborg; J P Niemi; R E Zigmond
Journal:  Neuroscience       Date:  2014-09-19       Impact factor: 3.590

7.  Tetracyclines and chemically modified tetracycline-3 (CMT-3) modulate cytokine secretion by lipopolysaccharide-stimulated whole blood.

Authors:  Julia Cazalis; Shin-ichi Tanabe; Guy Gagnon; Timo Sorsa; Daniel Grenier
Journal:  Inflammation       Date:  2009-04       Impact factor: 4.092

8.  A novel non-antibacterial, non-chelating hydroxypyrazoline derivative of minocycline inhibits nociception and oedema in mice.

Authors:  L F S Bastos; A Angusti; M C Vilaça; L A Merlo; E B Nascimento; L T S Rocha; A M Godin; A G R Solano; S Jarussophon; E A Nunan; Y Konishi; M M Coelho
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

9.  A novel action of minocycline: inhibition of human immunodeficiency virus type 1 infection in microglia.

Authors:  Qiusheng Si; Melissa Cosenza; Mee-Ohk Kim; Meng-Liang Zhao; Michael Brownlee; Harris Goldstein; Sunhee Lee
Journal:  J Neurovirol       Date:  2004-10       Impact factor: 2.643

10.  Doxycycline reduction of F-actin content of human neutrophils and fibroblasts.

Authors:  W L Gabler; J Smith; N Tsukuda
Journal:  Inflammation       Date:  1994-02       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.